FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.
EmergingBiotechs's picture

Email

Profile

User Points

  • General: 100
Total (all categories): -1750

History

No activity yet.

See More

Profire Energy (PFIE): Triple Digit Growth in the Third Quarter

Posted by EmergingBiotechs on November 22nd, 2011

Profire Energy Inc. (OTCBB:PFIE) is an innovative provider of safe and efficient burner management systems and services for use in oilfield combustion, with customers like Devon Energy Corporation (NYSE: DVN) and EnCana Corporation (NYSE: ECA), as well as smaller “mom and pop” oil and gas exploration and development companies.

Read More
comment 0
Share
Tickers:
DVN | ECA
Tags:
, DVN, Energy Stocks, energy sector, ECA, Profire Energy, PFIE, Devon Energy Corp, EnCana Corp

Cellceutix Files Investigational New Drug Application with FDA for Novel Cancer Drug
Posted by EmergingBiotechs on November 7th, 2011

With the hubbub around p53 as a potential breakthrough in cancer research, it is interesting to note that Cellceutix Corporation (OTCBB:CTIX) has submitted its Investigational New Drug application to the FDA. The news was posted on their website after the closing bell on Friday and released nationally this morning.

Read More
comment 0
Share
Tickers:
N/A
Tags:
, chemotherapy, Cellceutix, CTIX, Kevetrin, p53, new cancer drugs, Dana Farber

The Black Market for Diabetic Strips on Ebay - FOX News Baltimore ($ALRT)
Posted by EmergingBiotechs on October 31st, 2011

The Black Market for diabetic electronic test strips is a growing concern. As reported by several television stations, it is becoming a "business" for many, but contains great risk for diabetics that are turning to those sources for supplies. The video provided in the article is just one of many, but spotlights just how prevalent the problem truly is.

Read More
comment 0
Share
Tickers:
N/A
Tags:
, ALR Technologies, ALRT, Diabetes management, Black Market, Electrontronic Test Strips, Diabetic Care, Chronic Disease Management, Health-e-Connect

Unilife CEO to purchase up to U.S. $1.0 Million in $UNIS shares
Posted by EmergingBiotechs on August 18th, 2011

There is a whole community of traders who track and follow insider transactions. Unilife Corporation (NASDAQ:UNIS) has been seeing its fair share of insider buys with CEO Alan Shortall heading the purchases and growing a substantial position. ProActive Newsroom has followed Unilife closely and recently issued an article highlighting the Company.

An excerpt from the article,

Read More
comment 0
Share
Tickers:
UNIS
Tags:
, UNIS, prefilled syringe, safety syringe, Unilife, Alan Shortall, Insider Buys

Ventrus Biosciences Launches Phase III Trial for Hemorrhoid Therapy
Posted by EmergingBiotechs on August 17th, 2011

There are no FDA approved treatments for hemorrhoids currently, but Ventrus Biosciences (NASDAQ:VTUS) is aiming to change that fact. It was released yesterday by the Company that enrollment has commenced in Ventrus' pivotal Phase III trial studying VEN309 as a new therapy for hemorrhoids.

Read More
comment 0
Share
Tickers:
VTUS
Tags:
, clinical trials, Prescription Drugs, Ventrus Biosciences, VTUS, hemorrhoid therapy, VEN309

Unilife Begins the Supplying of Product to Sanofi - $UNIS
Posted by EmergingBiotechs on July 15th, 2011

Now settled-in to their new state-of-the-art facilities, Unilife has hit another milestone with the commencement of shipments of the Unifill syringe to Sanofi. This article discusses the next phase of the Unilife/Sanofi contract as well as features Alan Shortall, CEO of Unilife, in a brief video showing the proprietary syringe.

Article except:

Read More
comment 0
Share
Tickers:
CEO | UNIS
Tags:
, CEO, fda, UNIS, Unilife, Unifill, $UNIS, Alan Shortall, Unilife Medical Solutions, syringe, sanofi

The True Value of a SPA: An Inside Look at CorMedix
Posted by EmergingBiotechs on June 29th, 2011

With its new Special Protocol Assessment with the U.S. Food and Drug Administration, CorMedix will be conducting Phase III research for Deferiprone as an indication for Contrast-Induced Acute Kidney Injury. Often times, the importance or value of an SPA is overlooked, but it the case of CorMedix, it certainly warrants a closer look.

A portion of the article:

Read More
comment 0
Share
Tickers:
CRMD | SPA
Tags:
, Biotechnology Stocks, spa, CorMedix, CRMD, Neutrolin, Deferiprone

Pages